793 related articles for article (PubMed ID: 18562222)
1. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
2. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
Okamoto A; Shirakawa T; Bito T; Shigemura K; Hamada K; Gotoh A; Fujisawa M; Kawabata M
Urology; 2008 Jan; 71(1):156-60. PubMed ID: 18242386
[TBL] [Abstract][Full Text] [Related]
3. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.
Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA
J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367
[TBL] [Abstract][Full Text] [Related]
4. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
8. [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].
Li C; Yan RP; Yuan GH; Feng YG; Wang JS; Gao X; Huang YS; Zhou JB; Xie SS
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):733-6. PubMed ID: 17366782
[TBL] [Abstract][Full Text] [Related]
9. A new in vivo model to study invasion and metastasis of human bladder carcinoma.
Ahlering TE; Dubeau L; Jones PA
Cancer Res; 1987 Dec; 47(24 Pt 1):6660-5. PubMed ID: 3677100
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH
Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.
Chaffer CL; Brennan JP; Slavin JL; Blick T; Thompson EW; Williams ED
Cancer Res; 2006 Dec; 66(23):11271-8. PubMed ID: 17145872
[TBL] [Abstract][Full Text] [Related]
13. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mohammed SI; Bennett PF; Craig BA; Glickman NW; Mutsaers AJ; Snyder PW; Widmer WR; DeGortari AE; Bonney PL; Knapp DW
Cancer Res; 2002 Jan; 62(2):356-8. PubMed ID: 11809678
[TBL] [Abstract][Full Text] [Related]
14. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
Wu Y; McRoberts K; Berr SS; Frierson HF; Conaway M; Theodorescu D
Oncogene; 2007 Feb; 26(5):765-73. PubMed ID: 16878152
[TBL] [Abstract][Full Text] [Related]
15. DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Hahn NM; Waddell J; Olbricht GR; Zheng R; Stewart JC; Knapp DW
Urol Oncol; 2013 Nov; 31(8):1761-9. PubMed ID: 22609058
[TBL] [Abstract][Full Text] [Related]
16. Transitional cell carcinoma in fishing cats (Prionailurus viverrinus): pathology and expression of cyclooxygenase-1, -2, and p53.
Landolfi JA; Terio KA
Vet Pathol; 2006 Sep; 43(5):674-81. PubMed ID: 16966444
[TBL] [Abstract][Full Text] [Related]
17. Animal model of naturally occurring bladder cancer: characterization of four new canine transitional cell carcinoma cell lines.
Rathore K; Cekanova M
BMC Cancer; 2014 Jun; 14():465. PubMed ID: 24964787
[TBL] [Abstract][Full Text] [Related]
18. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
19. Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.
Liu H; Schwartz MJ; Hwang DH; Scherr DS
BJU Int; 2008 Apr; 101(7):894-901. PubMed ID: 18241249
[TBL] [Abstract][Full Text] [Related]
20. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression.
Webber MM; Quader ST; Kleinman HK; Bello-DeOcampo D; Storto PD; Bice G; DeMendonca-Calaca W; Williams DE
Prostate; 2001 Apr; 47(1):1-13. PubMed ID: 11304724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]